Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and GM-CSF plus full-dose chemoradiotherapy for unresectable advanced cervical cancer with high-risk factors
ChiCTR2100046592Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and sargramostim in Cervical Cancer (CC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Objective response rate and Toxic side effects. Started Jun 2021; status: recruiting.
02
Drugs
camrelizumabsargramostim
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2100046592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046592.